Tenmile invests in health technology companies and solutions that deliver
life-changing ideas and better health outcomes for all.
life-changing ideas and better health outcomes for all.
Portfolio 15
| Date | Name | Website | Total Raised | Location |
| 29.08.2024 | Sweetch | sweetch.com | $20M | Israel, Te... |
| - | Perx Healt... | perxhealth.com | $3M | United Sta... |
| - | CurveBeam ... | curvebeamai.com | - | United Sta... |
| - | Inventia L... | inventia.life | $35M | Australia,... |
| - | Emyria Lim... | emyria.com | - | Australia |
| - | LimmaTech ... | lmtbio.com | $39.5M | Switzerlan... |
| - | Mindset He... | mindsethealth.com | $17.8M | Australia,... |
| - | Carina Bio... | carinabiotech.com | - | Australia,... |
| - | Aravax | aravax.com.au | $62M | Australia,... |
| - | Revagenix | revagenix.com | - | - |
Show more
Mentions in press and media 2
| Date | Title | Description |
| 02.02.2024 | New investment brings LimmaTech’s series A to CHF 40 million | Emerging antimicrobial resistance worldwide presents a serious public health threat. Inappropriate or excessive use of antibiotics has resulted in a major increase in bacterial resistance against the formerly effective drugs. LimmaTech aim... |
| 20.12.2022 | Aravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile | Aravax, a clinical stage biotechnology company developing the first safe, convenient, and precisely targeted immunotherapeutic for peanut allergy (PVX108), today announces it has commenced its series B funding round with an investment of US... |